[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
Anemia is the most frequent haematological problem of chronic kidney disease (CKD). It begins in early stage of CKD and worsens with disease progression, affecting nearly all of predialysis patients. It is usually asymptomatic, therefore is underdiagnosed and undertreated. Anemia of CKD is predominantly a result of abnormal erythropoietin (EPO) production and iron deficiency. Renal anemia is associated with an increased risk of ischemic heart disease, left ventricular hypertrophy, chronic heart failure and higher cardiovascular morbidity and mortality. Patients et risk for CKD should be more often monitored for early detection of anemia so they could start with treatment on time. Recent studies show that erythropoeisis-stimulating agents (ESAs) are effective in predialysis especially if used with antihypertensive agents and statin. Correcting anemia in early stage kidney disease may delay progression to end-stage kidney disease (ESRD) and prolong time to start dialysis. Improved cardiac function in those patients reduce morbidity and mortality risk and improve quality of life (QoL) in patients with CKD.
Centar za dijalizu Internog odjela Opce bolnice Bjelovar. vesna.lovcic@bj.t-com.hr
Vesna
V
Lovcić
Jovana
J
Vujić
Renata
R
Ivanac Janković
Nikolina
N
Basić-Jukić
Ivan
I
Barisić
Petra
P
Lovcić
Marko
M
Dzapo
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D051436:Renal Insufficiency, Chronic / Q000145:classification / Q000150:complications*
D006397:Hematinics
Lijecenje anemije u bolesnika s kronicnom bubreznom bolesti koji jos nisu na dijalizi (stadiji 1.-4.).